Role of PDE4 Inhibitor Through Theobromine Topical Cream in Psoriasis

"Psoriasis" is a chronic, non-infectious autoimmune inflammatory disease affecting the skin, joints, and other systemic organs. It is primarily characterized by hyperproliferation and abnormal differentiation of keratinocytes, along with infiltration of immune cells into the dermal layer, resulting in red, scaly, and disfigured patches on the skin. The disease pathogenesis involves complex interactions among dendritic cells, T cells, and keratinocytes that activate TNF-α, IL-23/IL-17, and JAK/STAT pathways. Current therapies, such as topical corticosteroids, phototherapy, and biologics targeting specific cytokines, manifest considerable challenges, including adverse effects, treatment resistance, inconvenient administration, and prohibitive costs. Phosphodiesterase-4 (PDE4) inhibition represents a promising therapeutic strategy by preventing cAMP degradation and modulating inflammatory responses. Topical administration of a drug like Theobromine offers a significant advantage for psoriasis treatment, allowing targeted application to affected areas while minimizing systemic exposure and associated side effects.